Compare Alphabet Inc Class A (GOOGL) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Moderna, Inc. — how do they compare? Alphabet Inc Class A trades at $344.28 (market cap $4.20T), while Moderna, Inc. trades at $63.75 (market cap $24.18B). The key difference: Alphabet Inc Class A is far larger — about 173.7× Moderna, Inc.'s market cap, and Alphabet Inc Class A pays a 0.26% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| GOOGL | MRNA | |
|---|---|---|
Market Cap | $4.20T | $24.18B |
Sector | Media | Health |
52-Week High | $402.62 | $81.80 |
52-Week Low | $199.32 | $22.36 |
Enterprise Value | $4.09T | $20.33B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) is trading at $343.80, down 3.84% amid broader tech sector rotation. Despite the recent decline, the company maintains strong fundamentals with 2025 revenue of $402.84B and net income of $132.17B, representing a 32.8% profit margin. Technical indicators show bearish momentum with the stock testing support near $341, while analyst consensus remains overwhelmingly bullish with an 85% buy rating and $426.28 price target. Recent quarterly earnings have consistently exceeded expectations, with Q2 2026 EPS of $9.11 beating estimates by 217%.
The outlook remains positive given Alphabet's dominant market position, AI leadership, and strong cash flow generation. Key risks include antitrust scrutiny and tech sector volatility. With the stock trading below consensus targets and showing robust earnings growth, current levels present a potential entry point for long-term investors seeking exposure to AI and digital advertising growth.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
